- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06214377
Transcranial Direct Current Stimulation for Treating Parkinson´s Disease-related Pain in OFF State
Effects of Transcranial Direct Current Stimulation (tDCS) on Pain Modulation in Individuals With Parkinson's Disease in the Off State
Parkinson's Disease (PD) is a neurodegenerative disorder characterized by motor and non-motor symptoms. Pain is a significant symptom in PD, affecting a large percentage of patients and impacting their quality of life. The mechanisms of pain in PD involve complex changes in pain-modulating pathways, including dopaminergic and non-dopaminergic systems.
To address the lack of pain management strategies, the investigators propose exploring non-pharmacological therapies like transcranial direct current stimulation (tDCS). tDCS is a safe and non-invasive technique that modulates neuronal activity. It has shown positive effects on pain processing in healthy individuals and chronic pain patients, but its potential for PD-associated pain remains largely unexplored.
The primary motor cortex (M1) is a target for tDCS as it is believed to influence pain processing in other brain regions involved in sensory and emotional aspects. Initial studies suggest the benefits of tDCS in PD, including enhanced motor potentials and potential modulation of dopaminergic pathways. However, there are currently no published studies specifically investigating the effects of tDCS on PD-related pain, highlighting the need for further research.
A proof-of-concept trial is proposed to examine the effects of a single tDCS session on M1 in PD patients during the OFF state (without medication) and after taking dopaminergic medication. The study aims to assess the pain-relieving effects of tDCS in PD and explore potential synergies between tDCS and dopaminergic medication. By better understanding the impact of tDCS on pain relief in PD, this research may offer insights into alternative non-pharmacological approaches for managing pain in PD.
Study Overview
Status
Conditions
Detailed Description
Parkinson's Disease (PD) is a complex progressive neurodegenerative disorder. It is the second most common neurodegenerative disease, with a prevalence of 4.1 to 4.6 million people over the age of 50. It is estimated that these numbers will increase to 8.7 to 9.3 million by the year 2030.
PD is multisystemic and include both motor and non-motor symptoms. These symptoms can fluctuate throughout the day, leading PD patients to frequently experience two distinct states: the "on" state, when dopaminergic medication is active in their system, and the "off" state, which occurs when there is no medication concentration in the body, resulting in more severe symptoms.
Pain in PD is a highly relevant symptom that significantly impacts patients' quality of life, with a prevalence of up to 85% and moderate to severe intensity reported in 42% of individuals. Additionally, in Spain, the prevalence of PD-associated pain has significantly increased following the COVID-19 pandemic, with up to 50% of PD patients reporting daily pain. Moreover, pain in PD is often underreported, emphasizing the need to investigate its mechanisms and treatment.
The pathophysiological mechanisms of pain in PD are complex. In general, PD can lead to alterations in peripheral transmission, sensory-discriminative processing, pain perception, and interpretation at multiple levels, due to neurodegenerative changes in both dopaminergic and non-dopaminergic pain-modulating pathways. This dysregulation of the dopaminergic system can impact the experience of pain directly by enhancing nociceptive signals and indirectly by influencing expectations and the interpretation of such signals. However, it is considered that there is no specific pain center in PD patients but rather a pain matrix involving various brain structures.
Given the multiple central structures affected and their consequent pathophysiological mechanisms in PD-associated pain, there is a wide variety of clinical manifestations. These include musculoskeletal pain, generalized central chronic pain, visceral pain, pain related to "on-off" fluctuations, dystonic-dyskinetic pain, nocturnal immobility-related pain or restless legs syndrome, orofacial pain, inflammation or edema-related pain, and radicular pain.
Regarding the assessment of pain in PD, there is only one specific scale that evaluates all pain phenotypes of the disease in terms of intensity and frequency, namely the King's Parkinson's Disease Pain Scale (KPPS). Therefore, due to the scarcity of objective pain assessment tools and the crucial role of the central nervous system and endogenous modulation systems in the origin of PD-associated pain, it is important to assess pain processing characteristics such as Conditioned Pain Modulation (CPM), and Pressure Pain Thresholds (PPTs). CPM assesses the descending inhibitory pain system, and PPTs assess the intensity of pressure required to elicit initial pain in a specific body area.
Dopaminergic medication is the primary treatment for PD symptoms; however, its effects on pain management have shown contradictory results according to recent systematic reviews. Moreover, there is currently a lack of robust evidence to establish guidelines for pain management in PD, which is why non-pharmacological therapies have been proposed as a safe and useful alternative with fewer side effects.
Transcranial Direct Current Stimulation (tDCS) is a non-invasive form of brain stimulation in which a relatively weak continuous current is delivered to the cortical areas through small electrodes placed on the scalp. It is a neuromodulatory intervention, and based on the assumption that the exposed tissue is polarized, tDCS would modulate neuronal excitability by depolarizing or hyperpolarizing the resting membrane potential of neurons. This modulation would result in increases or decreases in cortical excitability, depending on whether the active electrode is the anode or the cathode, respectively.
tDCS has been shown to have an effect on certain psychophysical variables of pain processing in healthy subjects. It has primarily been shown to enhance CPM and improvements have been reported in PPTs, cold and heat pain thresholds, acute pain induced by laser (26), and pain threshold after peripheral electrical stimulation. Importantly, tDCS has also demonstrated beneficial effects in patients with chronic pain. Specifically, it has shown improvements in pain processing characteristics, resulting in clinical pain improvements in other populations with chronic neuropathic pain. It is hypothesized that tDCS could be an effective alternative in the treatment of pain with central sensitization components, a process common in PD-associated pain.
The majority of the hypoalgesic effects generated by tDCS are due to its modulation of the primary motor cortex (M1). It is suggested that tDCS over M1 could reduce pain by increasing excitability not only in the stimulated area but also in other structures involved in pain processing, both sensory and emotional, through cortico-subcortical connectivity.
However, there are currently no published studies applying tDCS for the treatment of PD-associated pain, except for unpublished studies from our group confirming a favorable effect in this regard. Nonetheless, disregarding our results, its use can be considered safe as it has already been tested in PD patients for other purposes. tDCS has demonstrated an influence on Motor Evoked Potentials (MEPs) in PD patients, increasing MEPs after stimulating M1 with an active anode and decreasing MEPs with an active cathode. Furthermore, it has been observed that bilateral tDCS with an active anode leads to increases in BDNF, thus slowing down the degeneration of dopaminergic neurons. This last piece of evidence, along with other findings that demonstrate the capacity of tDCS to modulate dopaminergic transmission, is relevant for the present project, considering that part of the descending inhibitory pain system involves these pathways. Similarly, it has been demonstrated that pain causes reductions in corticomotor excitability, governed by M1, and tDCS applied to M1 has shown the ability to increase cortical excitability, which has abnormal activity in PD patients and could influence their pain.
Given the overlap between many influential areas in PD-associated pain and the areas excited by tDCS over M1, with these increases in excitability correlating with pain reduction, as well as the potential effect of tDCS on dopaminergic pathways, a hypoalgesic effect of tDCS in PD patients in their OFF state is hypothesized. Additionally, if the action is based on the activation of dopaminergic pathways, a possible enhancement of dopaminergic medication's action with better pain control during the ON period is also expected. However, there is currently no study that has specifically evaluated this effect in PD patients in the OFF state, making it pertinent to conduct a proof-of-concept trial with this objective. The objective is to determine the effect of a single session of treatment using transcranial direct current stimulation (tDCS) on the primary motor cortex (M1) on perceived clinical pain and pain processing characteristics in patients with Parkinson's disease (PD) in the OFF state (without dopaminergic medication) and after taking dopaminergic medication.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Juan Pablo Romero, MD, PhD
- Phone Number: 1688 +34917091400
- Email: p.romero.prof@ufv.es
Study Locations
-
-
-
Madrid, Spain, 28007
- Recruiting
- Hospital Beata María Ana
-
Contact:
- Juan Pablo Romero, MD. PhD
- Phone Number: 1688 +34917091400
- Email: p.romero.prof@ufv.es
-
Principal Investigator:
- Josué Fernández Carnero, MD. PhD
-
Sub-Investigator:
- Yeray González Zamorano, PT. Msc
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of Idiopathic Parkinson´s Disease.
- Presence of Parkinson´s Disease-related pain in the off-state.
- Neuroimaging study without previous pathologies.
- Score > 5 in transfers (bed to chair and back) item in Barthel Index.
- Score = or > 26 in Montreal Cognitive Assessment (MoCA).
- Tolerability for the application of electrotherapy.
- Able to provide informed consent to participate in the study
- Pain intensity >= 3 in Visual Analogue Scale or equivalent.
Exclusion Criteria:
- Neurologic disease different from PD.
- Pain non-related to PD.
- Dermatologic problems, wounds, or ulcers in the electrode's application area.
- Presence of implants or metal pieces in the head.
- Presence of cardiac pacemaker, vagal, brain or transcutaneous stimulators, medication pumps, ventriculoperitoneal shunts or aneurysm clips.
- Significative difficulties in language.
- History of alcohol or drugs abuse.
- Non-controlled medical problems.
- Pregnancy.
- Epilepsy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active Transcranial Direct Current Stimulation and dopaminergic medication
Active Transcranial Direct Current Stimulation (atDCS) will be applied over the Primary Motor Cortex (M1) contralateral to pain if it is unilateral, or always on the left M1 if pain is bilateral.
It will consist of 1 session of 20 minutes of conventional stimulation (anode over M1) at 2 mA.
It will be applied in the OFF state (i.e., >12h after the last medication intake).
Lately, patients will take its usual dopaminergic medication.
|
The Starstim tCS® equipment will be used, with 35 cm2 sponge electrodes.
The tDCS over M1 will be performed by placing the active anode on the C3 point (10/20 EEG system) and the cathode on the contralateral supraorbital area (Fp2).
Regarding the stimulated hemisphere, in cases of asymmetric pain, it will be applied to the contralateral M1, and in cases of bilateral pain, it will be applied to the M1 of the dominant hemisphere.
A constant current of 2 mA (subthreshold intensity) will be applied for 20 minutes, with the first 30 seconds used as a ramp-up and the last 30 seconds as a ramp-down.
Number of sessions: 1.
The Starstim tCS® equipment (Neuroelectrics Inc, Barcelona, Spain) will be used with 35 cm2 sponge electrodes.
The tDCS sham over M1 will be performed by placing the electrodes in the same position as in the active tDCS protocol.
However, the stimulator will automatically turn off after 30 seconds of stimulation, making it a reliable sham stimulation method.
Therefore, subjects will feel the same tingling sensation but will not receive current for the remainder of the stimulation time.
After tDCS, the participant will take their regular dopaminergic medication in order to go from OFF state to ON state.
|
Sham Comparator: : Sham Transcranial Direct Current Stimulation and dopaminergic medication
Sham Transcranial Direct Current (s-tDCS) will be applied over the Primary Motor Cortex with the same procedure, during 1 session of 20 minutes of conventional stimulation.
It will be applied in the OFF state (i.e., >12h after the last medication intake).
Lately, patients will take its usual dopaminergic medication.
|
The Starstim tCS® equipment will be used, with 35 cm2 sponge electrodes.
The tDCS over M1 will be performed by placing the active anode on the C3 point (10/20 EEG system) and the cathode on the contralateral supraorbital area (Fp2).
Regarding the stimulated hemisphere, in cases of asymmetric pain, it will be applied to the contralateral M1, and in cases of bilateral pain, it will be applied to the M1 of the dominant hemisphere.
A constant current of 2 mA (subthreshold intensity) will be applied for 20 minutes, with the first 30 seconds used as a ramp-up and the last 30 seconds as a ramp-down.
Number of sessions: 1.
The Starstim tCS® equipment (Neuroelectrics Inc, Barcelona, Spain) will be used with 35 cm2 sponge electrodes.
The tDCS sham over M1 will be performed by placing the electrodes in the same position as in the active tDCS protocol.
However, the stimulator will automatically turn off after 30 seconds of stimulation, making it a reliable sham stimulation method.
Therefore, subjects will feel the same tingling sensation but will not receive current for the remainder of the stimulation time.
After tDCS, the participant will take their regular dopaminergic medication in order to go from OFF state to ON state.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Conditioned Pain Modulation
Time Frame: From baseline to immediately post tDCS
|
Assesses the descending pain modulatory system.
The Pain Pressure Threshold will be assessed in the middle ofthe distal phalanx of the thumb with ta handheld algometer, corresponding to the first test stimulus.
Afterward, the patient will immerse the contrary hand up to the wrist into stirred ice-cold water (0-4º) maintaining it for 3 minutes, corresponding to the conditioning stimulus.
If the pain is unbearable before the 3 minutes, the patient will be able to remove his/her hand.
Immediately after removing the hand, a second Pain Pressure Threshold measure will be performed in the same place as the first one, corresponding to the second test stimulus.
After 1-minute rest, a third Pain Pressure Threshold will be measured to assess the Conditioned Pain Modulation residual functioning.
|
From baseline to immediately post tDCS
|
Change in Conditioned Pain Modulation
Time Frame: From baseline to immediately post dopaminergic medication
|
Assesses the descending pain modulatory system.
The Pain Pressure Threshold will be assessed in the middle ofthe distal phalanx of the thumb with ta handheld algometer, corresponding to the first test stimulus.
Afterward, the patient will immerse the contrary hand up to the wrist into stirred ice-cold water (0-4º) maintaining it for 3 minutes, corresponding to the conditioning stimulus.
If the pain is unbearable before the 3 minutes, the patient will be able to remove his/her hand.
Immediately after removing the hand, a second Pain Pressure Threshold measure will be performed in the same place as the first one, corresponding to the second test stimulus.
After 1-minute rest, a third Pain Pressure Threshold will be measured to assess the Conditioned Pain Modulation residual functioning.
|
From baseline to immediately post dopaminergic medication
|
Changes in Pain Pressure Threshold
Time Frame: From baseline to immediately post tDCS
|
Two Pain Pressure Thresholds will be measured by a handheld algometer, one over the most painful area (peripheric hyperalgesia) and the other one over the middle of the distal phalanx of the thumb (central hyperalgesia). The Pain Pressure Threshold will be applied with the algometer perpendicular to the skin increasing at a rate of 1 kg/s until the first sensation of pain. 3 measures with 30-seconds rest between pulses will be performed, taking the average as Pain. Pressure Threshold. |
From baseline to immediately post tDCS
|
Changes in Pain Pressure Threshold
Time Frame: From baseline to immediately post dopaminergic medication
|
Two Pain Pressure Thresholds will be measured by a handheld algometer, one over the most painful area (peripheric hyperalgesia) and the other one over the middle of the distal phalanx of the thumb (central hyperalgesia). The Pain Pressure Threshold will be applied with the algometer perpendicular to the skin increasing at a rate of 1 kg/s until the first sensation of pain. 3 measures with 30-seconds rest between pulses will be performed, taking the average as Pain. Pressure Threshold. |
From baseline to immediately post dopaminergic medication
|
Changes in Visual Numeric Pain Rating Scale
Time Frame: From baseline to immediately post tDCS
|
It will be used to measure pain intensity due to its high discriminatory power.
The scale assesses pain intensity using numbers or words through various types of scales ranging from 0 to 10. Pain rating ranges from 0 (no pain), 1-3 (mild pain, mild discomfort or irritation, slight impairment in daily activities), 4-6 (moderate pain, significant impairment in daily activities), and 7-10 (severe pain, inability to perform daily activities).
|
From baseline to immediately post tDCS
|
Changes in Visual Numeric Pain Rating Scale
Time Frame: From baseline to immediately post dopaminergic medication
|
It will be used to measure pain intensity due to its high discriminatory power.
The scale assesses pain intensity using numbers or words through various types of scales ranging from 0 to 10. Pain rating ranges from 0 (no pain), 1-3 (mild pain, mild discomfort or irritation, slight impairment in daily activities), 4-6 (moderate pain, significant impairment in daily activities), and 7-10 (severe pain, inability to perform daily activities).
|
From baseline to immediately post dopaminergic medication
|
Changes in Global Rating of Change
Time Frame: From baseline to immediately post tDCS
|
It will be used to measure the self-perceived change in the patient's pain state.
Its main objective is to quantify the extent to which a patient has improved or worsened over a specific period of time.
It involves a single question asked to the patient to rate their change compared to the pre-intervention state, and the scores will range from -7 (much worse than before), through 0 (same as before), to +7 (much better than before).
|
From baseline to immediately post tDCS
|
Changes in Global Rating of Change
Time Frame: From baseline to immediately post dopaminergic medication
|
It will be used to measure the self-perceived change in the patient's pain state.
Its main objective is to quantify the extent to which a patient has improved or worsened over a specific period of time.
It involves a single question asked to the patient to rate their change compared to the pre-intervention state, and the scores will range from -7 (much worse than before), through 0 (same as before), to +7 (much better than before).
|
From baseline to immediately post dopaminergic medication
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Brain Symmetry Index in electroencephalography
Time Frame: From baseline to immediately post tDCS
|
Resting state EEG: A 64-channel EEG recording will be performed at rest for 3 minutes following the standard protocol for baseline assessment. Tapping EEG: A 64-channel EEG recording will be conducted while performing a tapping task for 30 seconds. The recording will be done separately for each hand, starting with the dominant hand. Closed-Eyes EEG: A 64-channel EEG recording will be conducted while participants have their eyes closed for 5 minutes. |
From baseline to immediately post tDCS
|
Changes in Brain Symmetry Index in electroencephalography
Time Frame: From baseline to immediately post dopaminergic medication
|
Resting EEG: A 64-channel EEG recording will be performed at rest for 3 minutes following the standard protocol for baseline assessment. Tapping EEG: A 64-channel EEG recording will be conducted while performing a tapping task for 30 seconds. The recording will be done separately for each hand, starting with the dominant hand. Closed-Eyes EEG: A 64-channel EEG recording will be conducted while participants have their eyes closed for 5 minutes. |
From baseline to immediately post dopaminergic medication
|
Changes in Unified Parkinson´s Disease Rating Scale
Time Frame: From baseline to immediately post dopaminergic medication
|
It is a quantitative scale that collects information about the frequency and severity of motor symptoms.
Higher scores indicate a greater degree of impairment.
The minumum value is 0 and the maximum is 68.
|
From baseline to immediately post dopaminergic medication
|
Changes in Finger tapping task
Time Frame: From baseline to immediately post dopaminergic medication
|
Finger Taping task, where the participants will be instructed to press the space bar on the keyboard as fast as possible and repeatedly with the index finger, to measure motor function.
|
From baseline to immediately post dopaminergic medication
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain Catastrophizing Scale
Time Frame: Baseline
|
Measures catastrophizing thinking.
Its total score range from 0-52, along with three subscale scores assessing rumination, magnification and helplessness, with higher scores indicating higher level of catastrophizing.
|
Baseline
|
King´s Parkinson´s Disease Pain Scale score
Time Frame: Baseline
|
Parkinson´s Disease specific scale that evaluates the localization, frequency, and intensity of pain.
It has 14 items distributed in 7 domains: 1. Musculoskeletal Pain; 2. Chronic Pain; 3. Fluctuation-related Pain; 4. Nocturnal Pain; 5. Oro-facial Pain; 6. Discoloration, Oedema/Swelling Pain; 7. Radicular Pain.
Each item is scored by severity (0, none to 3, very severe) multiplied by frequency (0, never to 4, all the time) resulting in a subscore of 0 to 12, the sum of which gives the total score with a theoretical range from 0 to 168, with higher scores indicating more severity and frequency of pain.
|
Baseline
|
Brief Pain Inventory score
Time Frame: Baseline
|
It contains 15 items, including 2 multi-item scales to measure the intensity of pain and its impact on the function and welfare of patients.
It also presents open questions to assess the localization of pain and the treatment used for its management, just as its effectiveness.
Scores oscillate from 0 to 110, with higher scores indicating more pain and more impact on function and welfare of patients
|
Baseline
|
Beck´s Depression Inventory
Time Frame: Baseline
|
Measures depressive symptoms.
Scores range from 0 to 63 leading to 6 groups: 0-10, normal; 11-16, mild mood disturbance; 17-20, borderline clinical depression; 21-30, moderate depression; 31-40, severe depression; and over 40, extreme depression
|
Baseline
|
State-Trait Anxiety Inventory
Time Frame: Baseline
|
Measures anxious states and anxious traits.
It has 20 items for assessing trait anxiety and 20 for state anxiety.
All items are rated on a 4-point scale (e.g., from "Almost Never" to "Almost Always").
Higher scores indicate greater anxiety
|
Baseline
|
Tampa Scale of Kinesiophobia
Time Frame: Baseline
|
Measures fear of movement-related pain.
Its scores range from 11-44 points with higher scores indicating greater fear of pain, movement, and injury
|
Baseline
|
PD-specific 16-items Parkinson Fatigue Scale
Time Frame: Baseline
|
It is a scale that measures the specific fatigue experienced by patients with Parkinson's disease.
It consists of 16 items with five response categories ranging from 0 (strongly disagree) to 4 (strongly agree).
The final sum of these items yields a total score ranging from zero to 64, with higher scores indicating higher levels of fatigue.
If the scale is not available in Spanish, either the Fatigue Severity Scale (FSS) or the Multidimensional Fatigue Inventory (MFI) will be used, as they have been validated for Parkinson's disease and recommended by the International Parkinson and Movement Disorder Society (MDS).
|
Baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Juan Pablo Romero, MD, PhD, Universidad Francisco de Vitoria, Facultad de Ciencias Experimentales
- Principal Investigator: Josué Fernández Carnero, PT, PhD, Universidad Rey Juan Carlos
- Principal Investigator: Marcos Moreno Verdú, PT, PhD, Universidad Francisco de Vitoria
Publications and helpful links
General Publications
- Lefaucheur JP, Antal A, Ayache SS, Benninger DH, Brunelin J, Cogiamanian F, Cotelli M, De Ridder D, Ferrucci R, Langguth B, Marangolo P, Mylius V, Nitsche MA, Padberg F, Palm U, Poulet E, Priori A, Rossi S, Schecklmann M, Vanneste S, Ziemann U, Garcia-Larrea L, Paulus W. Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS). Clin Neurophysiol. 2017 Jan;128(1):56-92. doi: 10.1016/j.clinph.2016.10.087. Epub 2016 Oct 29.
- Fregni F, Boggio PS, Lima MC, Ferreira MJ, Wagner T, Rigonatti SP, Castro AW, Souza DR, Riberto M, Freedman SD, Nitsche MA, Pascual-Leone A. A sham-controlled, phase II trial of transcranial direct current stimulation for the treatment of central pain in traumatic spinal cord injury. Pain. 2006 May;122(1-2):197-209. doi: 10.1016/j.pain.2006.02.023. Epub 2006 Mar 27.
- Fregni F, Boggio PS, Santos MC, Lima M, Vieira AL, Rigonatti SP, Silva MT, Barbosa ER, Nitsche MA, Pascual-Leone A. Noninvasive cortical stimulation with transcranial direct current stimulation in Parkinson's disease. Mov Disord. 2006 Oct;21(10):1693-702. doi: 10.1002/mds.21012.
- Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015 Aug 29;386(9996):896-912. doi: 10.1016/S0140-6736(14)61393-3. Epub 2015 Apr 19.
- Silverdale MA, Kobylecki C, Kass-Iliyya L, Martinez-Martin P, Lawton M, Cotterill S, Chaudhuri KR, Morris H, Baig F, Williams N, Hubbard L, Hu MT, Grosset DG; UK Parkinson's Pain Study Collaboration. A detailed clinical study of pain in 1957 participants with early/moderate Parkinson's disease. Parkinsonism Relat Disord. 2018 Nov;56:27-32. doi: 10.1016/j.parkreldis.2018.06.001. Epub 2018 Jun 6.
- Antonini A, Tinazzi M, Abbruzzese G, Berardelli A, Chaudhuri KR, Defazio G, Ferreira J, Martinez-Martin P, Trenkwalder C, Rascol O. Pain in Parkinson's disease: facts and uncertainties. Eur J Neurol. 2018 Jul;25(7):917-e69. doi: 10.1111/ene.13624. Epub 2018 Apr 18.
- Chaudhuri KR, Rizos A, Trenkwalder C, Rascol O, Pal S, Martino D, Carroll C, Paviour D, Falup-Pecurariu C, Kessel B, Silverdale M, Todorova A, Sauerbier A, Odin P, Antonini A, Martinez-Martin P; EUROPAR and the IPMDS Non Motor PD Study Group. King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation. Mov Disord. 2015 Oct;30(12):1623-31. doi: 10.1002/mds.26270. Epub 2015 Jun 11.
- Perez-Lloret S, Ciampi de Andrade D, Lyons KE, Rodriguez-Blazquez C, Chaudhuri KR, Deuschl G, Cruccu G, Sampaio C, Goetz CG, Schrag A, Martinez-Martin P, Stebbins G; Members of the MDS Committee on Rating Scales Development. Rating Scales for Pain in Parkinson's Disease: Critique and Recommendations. Mov Disord Clin Pract. 2016 Jun 24;3(6):527-537. doi: 10.1002/mdc3.12384. eCollection 2016 Nov-Dec.
- Imai Y, Petersen KK, Morch CD, Arendt Nielsen L. Comparing test-retest reliability and magnitude of conditioned pain modulation using different combinations of test and conditioning stimuli. Somatosens Mot Res. 2016 Sep-Dec;33(3-4):169-177. doi: 10.1080/08990220.2016.1229178. Epub 2016 Sep 20.
- Santos-Garcia D, Oreiro M, Perez P, Fanjul G, Paz Gonzalez JM, Feal Painceiras MJ, Cores Bartolome C, Valdes Aymerich L, Garcia Sancho C, Castellanos Rodrigo MDM. Impact of Coronavirus Disease 2019 Pandemic on Parkinson's Disease: A Cross-Sectional Survey of 568 Spanish Patients. Mov Disord. 2020 Oct;35(10):1712-1716. doi: 10.1002/mds.28261. Epub 2020 Sep 22.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Parkinson Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Protective Agents
- Cardiotonic Agents
- Dopamine Agents
- Sympathomimetics
- Dopamine
- Dopamine Agonists
Other Study ID Numbers
- ParkOFF-tDCS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
Clinical Trials on Active Transcranial Direct Current Stimulation
-
Louisiana State University and A&M CollegeNot yet recruitingParkinson Disease
-
Holland Bloorview Kids Rehabilitation HospitalRecruitingStroke | Traumatic Brain Injury | Acquired Brain Injury | HemiparesisCanada
-
University of LiegeResearch Center of Neurology, Russia; Fondazione Salvatore Maugeri, Italy; Université... and other collaboratorsCompletedDisorder of ConsciousnessBelgium
-
Universidad Francisco de VitoriaUniversidad Nacional de Educación a Distancia; Hospital Beata María AnaNot yet recruitingCerebral Palsy | Paediatric Stroke | Paediatric Brain Damage | Paediatric Traumatic Brain Injury | Paediatric Acquired Brain InjurySpain
-
Taipei Veterans General Hospital, TaiwanRecruiting
-
Universidad Francisco de VitoriaUniversidad Rey Juan Carlos; Hospital Beata María AnaCompletedPain | Parkinson DiseaseSpain
-
Federal University of São PauloUniversity of Pittsburgh; Universidade Federal do AmapáCompleted
-
D'Or Institute for Research and EducationCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional... and other collaboratorsCompleted
-
Centre Hospitalier St AnneNot yet recruiting
-
Manhattan Psychiatric CenterCompletedSchizophrenia | Auditory HallucinationUnited States